Oncoustics develops ultrasound-based tissue characterization solutions that apply AI to raw ultrasound signals for noninvasive surveillance, diagnostics, and treatment monitoring. Its first product, the OnX Liver Assessment Solution, focuses on detecting structural liver diseases including fibrosis and steatosis. The company intends to advance its SaMD (software as a medical device) technology to enable low-cost assessment of structural diseases at point of care. Oncoustics plans regulatory submissions for the OnX solution in the United States (FDA 510(k)), Canada (Health Canada medical device license), and the European Union (CE Mark). The OnX Liver Assessment Solution has not been cleared for clinical use and is For Investigational Use Only. The company is led by CEO Beth Rogozinski.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2022